A Real-World Study on Extranodal Lymphoma

The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Lymphoma Diffuse Large B Cell Lymphoma Extranodal Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Lymphoma is a common hematological malignancy. Many different pathologic types of lymphoma can originate in extranodal organs or be associated with extranodal organ involvement. For lymphoma with extranodal involvement, conventional regimens often cannot provide satisfactory results for patients. This study aims to prospectively collect clinical information on patients with extranodal DLBCL, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the the best therapeutic strategies in the real-world population.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years (including 18 years old).
Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined.
Patients who have received systematic clinical treatment.
Patients with measurable lesions, at least containing one effective evaluation of efficacy.

Exclusion criteria

Patients who only receive supportive treatment.
Patients who cannot obtain effective evaluation data of efficacy.

Treatment and study plan

No interventions need to be specified for this study

Other

No interventions need to be specified for this study

Primary outcomes

Progression Free Survival (PFS)

Time frame: Baseline up to data cut-off (up to approximately 1 year)

Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.

Secondary outcomes

Overall Survival (OS)

Time frame: Baseline up to data cut-off (up to approximately 1 year)

Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.

Study contacts

Contact information is provided by the study sponsor or research team.

Pengpeng Xu, MD

CONTACT

[email protected]

+862164370045 ext. 610707

Weili Zhao, MD, PhD

CONTACT

[email protected]

+862164370045 ext. 610707

Sponsors and collaborators

Lead sponsor

Ruijin Hospital

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2027
Study completion: 2029
First posted: Aug 27, 2024
Registry last updated: Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed